Island Pharmaceuticals Limited (ASX:ILA)
Australia · Delayed Price · Currency is AUD 0.4300
+0.0050 (1.18%)
Sep 2, 2026, 11:44 AM AEST
Island Pharmaceuticals Company Description
Island Pharmaceuticals Limited, a drug repurposing company, focuses on the development of antiviral therapeutics for infectious diseases in Australia and the United States.
The company’s lead product candidate is ISLA-101, a drug which is in second clinical-stage for the prevention and treatment of dengue fever and other mosquito vector borne diseases; and Galidesivir, a spectrum antiviral candidate with the potential to address multiple high-priority RNA virus threats.
Island Pharmaceuticals Limited was founded in 2017 and is based in Hawthorn East, Australia.
Island Pharmaceuticals Limited
| Country | Australia |
| Founded | 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | David Foster |
Contact Details
Address: 117 Camberwell Road Hawthorn East, VIC 3123 Australia | |
| Phone | 61 3 7036 7675 |
| Website | islandpharmaceuticals.com |
Stock Details
| Ticker Symbol | ILA |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000138869 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. David Charles Foster J.D., M.A.I.C.D., Ph.D. | MD, Chief Executive Officer, President and Executive Director |
| Cameron Peter Jones C.A. | Chief Financial Officer and Company Secretary |